
0:00
11:42
PGY2 SOT Gillian Stiger joins us from the Hospital of the University of Pennsylvania to discuss “Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study”, as well as a discussion on her residency experience with belatacept rapid conversion for a patient with thrombotic microangiopathy associated with tacrolimus.
Fler avsnitt från "The mTOR You Know"



Missa inte ett avsnitt av “The mTOR You Know” och prenumerera på det i GetPodcast-appen.








